Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luxeptinib in Relapsed/Refractory CLL/SLL/NHL
NCT03893682Phase 1Terminated
- Sponsor
- Aptose Biosciences Inc.
- Start
- Apr 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of luxeptinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), sponsored by Aptose Biosciences Inc. Primary endpoints: Incidence of treatment-emergent adverse events of CG-806, Establish a CG-806 dose that maintains a biologically active plasma concentration and 1 more. Started Apr 2019; status: terminated.
02
Drugs
luxeptinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03893682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893682.